array(3) { ["company_details"]=> array(13) { ["name"]=> string(28) "Bristol-Myers Squibb Company" ["slug"]=> string(37) "81631-us-bristol-myers-squibb-company" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13" ["description"]=> string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html" ["address_street"]=> string(19) "430 E 29TH St FL 14" ["address_place"]=> string(8) "New York" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1887-02-28" ["website_domain"]=> string(7) "bms.com" ["website_url"]=> string(19) "https://www.bms.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(1200) ["article_count"]=> int(2511) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(118) "BMS signs 'big deal' worth 2.5 trillion won with Repertoire... Development of 3 types of autoimmune disease treatments" ["snippet_en"]=> string(387) "[The Bio Reporter Yoo Ha-eun] On the 29th (local time), Bristol Myers Squibb (BMS), a multinational pharmaceutical company, signed a contract with Repertoire Immune Medicines (hereinafter referred to as Repertoire), an American biotechnology company, to develop three types of vaccines resistant to autoimmune diseases. announced that it had signed a cooperation agreement with for teeth" ["url"]=> string(59) "https://www.thebionews.net/news/articleView.html?idxno=4812" ["image_url"]=> NULL ["source"]=> string(14) "thebionews.net" ["publication_date"]=> string(10) "2024-05-01" ["categories"]=> array(4) { [0]=> string(13) "Collaboration" [1]=> string(5) "Award" [2]=> string(15) "Deals & Tenders" [3]=> string(5) "R & D" } } [1]=> array(7) { ["title_en"]=> string(81) "France's Sanofi boosts rare disease business with about $2.2 billion Inhibrx deal" ["snippet_en"]=> string(247) "The companies said the deal will give Sanofi access to Inhibrx's INBRX-101, currently in the second of three phases of clinical trials, while its other experimental drugs will be spun off into a separate company, with Sanofi retaining an 8% stake." ["url"]=> string(75) "https://ca.finance.yahoo.com/news/frances-sanofi-buy-u-drugs-063215685.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6e936cb5-7957-4f27-9507-368074f4ff67" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2024-01-23" ["categories"]=> array(4) { [0]=> string(11) "Acquisition" [1]=> string(15) "Deals & Tenders" [2]=> string(25) "Business Model Resilience" [3]=> string(20) "Business Development" } } [2]=> array(7) { ["title_en"]=> string(74) "Bristol-Myers plans billion-dollar acquisition | Stock exchanges newspaper" ["snippet_en"]=> string(105) "The pharmaceutical company Bristol-Myers Squibb plans to take over Karuna. The deal is worth $14 billion." ["url"]=> string(88) "https://www.boersen-zeitung.de/unternehmen-branchen/bristol-myers-plant-milliardenzukauf" ["image_url"]=> string(78) "https://images.businessradar.com/articles/63bf47c9-fc1c-4117-ac8e-9e357e28b031" ["source"]=> string(18) "boersen-zeitung.de" ["publication_date"]=> string(10) "2023-12-22" ["categories"]=> array(5) { [0]=> string(11) "Acquisition" [1]=> string(15) "Deals & Tenders" [2]=> string(25) "Business Model Resilience" [3]=> string(12) "Stock Market" [4]=> string(21) "Competitive Behaviour" } } [3]=> array(7) { ["title_en"]=> string(98) "Fierce Pharma Asia—BMS’ $8.4B ADC bet; China’s reimbursement update; FDA’s CAR-T roadblock" ["snippet_en"]=> string(278) "Bristol Myers Squibb inked an antibody-drug conjugate (ADC) licensing deal worth up to $8.4 billion. AstraZeneca and Gilead's ADCs passed on China's national insurance scheme. | Bristol Myers Squibb inked an antibody-drug conjugate (ADC) licensing deal worth up to $8.4 billion." ["url"]=> string(90) "https://www.fiercepharma.com/pharma/bms-huge-adc-bet-china-nrdl-update-fda-car-t-roadblock" ["image_url"]=> string(78) "https://images.businessradar.com/articles/33f911a0-09c9-4adb-94aa-3b864c8902f0" ["source"]=> string(16) "fiercepharma.com" ["publication_date"]=> string(10) "2023-12-15" ["categories"]=> array(3) { [0]=> string(11) "Competition" [1]=> string(15) "Deals & Tenders" [2]=> string(7) "Opening" } } [4]=> array(7) { ["title_en"]=> string(90) "Karyopharm Enters Clinical Trial Collaboration, Supply Agreement With Bristol-Myers Squibb" ["snippet_en"]=> string(280) "(RTTNews) - Karyopharm Therapeutics Inc. (KPTI) has entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb (BMY) to evaluate the investigational cereblon E3 ligase modulator agent mezigdomide in combination with Karyopharm's selinexor, an appro" ["url"]=> string(121) "https://www.nasdaq.com/articles/karyopharm-enters-clinical-trial-collaboration-supply-agreement-with-bristol-myers-squibb" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-10-30" ["categories"]=> array(4) { [0]=> string(13) "Collaboration" [1]=> string(5) "Legal" [2]=> string(15) "Deals & Tenders" [3]=> string(23) "Supply Chain Management" } } [5]=> array(7) { ["title_en"]=> string(71) "Bristol-Myers Squibb shells out billions for Mirati: 5 big deal reports" ["snippet_en"]=> string(71) "Bristol-Myers Squibb shells out billions for Mirati: 5 big deal reports" ["url"]=> string(126) "https://www.investing.com/news/stock-market-news/bristolmyers-squibb-shells-out-billions-for-mirati-5-big-deal-reports-3193553" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-10-09" ["categories"]=> array(2) { [0]=> string(11) "Acquisition" [1]=> string(15) "Deals & Tenders" } } [6]=> array(7) { ["title_en"]=> string(50) "Samsung Biologics inks $242 mil. CMO deal with BMS" ["snippet_en"]=> string(295) "Samsung Biologics signed a $242 million contract manufacturing organization (CMO) deal with global pharmaceutical giant Bristol-Myers Squibb for the production of immuno-oncology drugs, the drug manufacturer said Monday. Samsung said the production agreement was made with BMS' subsidiary Swords" ["url"]=> string(63) "https://www.koreatimes.co.kr/www/nation/2023/11/129_359477.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d32b6dfd-0584-46f2-959d-1eac6341f66a" ["source"]=> string(16) "koreatimes.co.kr" ["publication_date"]=> string(10) "2023-09-18" ["categories"]=> array(6) { [0]=> string(20) "Contract negotiation" [1]=> string(17) "Production Issues" [2]=> string(11) "Acquisition" [3]=> string(15) "Deals & Tenders" [4]=> string(23) "Supply Chain Management" [5]=> string(21) "Competitive Behaviour" } } [7]=> array(7) { ["title_en"]=> string(93) "HSBC Securities lifts Bristol-Myers Squibb Company [BMY] price estimate. Who else is bullish?" ["snippet_en"]=> string(294) "Bristol-Myers Squibb Company [NYSE: BMY] slipped around -0.46 points on Friday, while shares priced at $59.03 at the close of the session, down -0.77%. The company report on September 17, 2023 at 7:57 PM that Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to" ["url"]=> string(123) "https://dbtnews.com/2023/09/18/hsbc-securities-lifts-bristol-myers-squibb-company-bmy-price-estimate-who-else-is-bullish-2/" ["image_url"]=> NULL ["source"]=> string(11) "dbtnews.com" ["publication_date"]=> string(10) "2023-09-18" ["categories"]=> array(2) { [0]=> string(13) "Collaboration" [1]=> string(15) "Deals & Tenders" } } [8]=> array(7) { ["title_en"]=> string(50) "Samsung Biologics inks $242 mil. CMO deal with BMS" ["snippet_en"]=> string(295) "Samsung Biologics signed a $242 million contract manufacturing organization (CMO) deal with global pharmaceutical giant Bristol-Myers Squibb for the production of immuno-oncology drugs, the drug manufacturer said Monday. Samsung said the production agreement was made with BMS' subsidiary Swords" ["url"]=> string(61) "https://www.koreatimes.co.kr/www/tech/2023/09/129_359477.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/e7c635b7-2e89-42dd-9c37-5a717bcc9b75" ["source"]=> string(16) "koreatimes.co.kr" ["publication_date"]=> string(10) "2023-09-18" ["categories"]=> array(2) { [0]=> string(21) "Competitive Behaviour" [1]=> string(15) "Deals & Tenders" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(252) } [1]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(165) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(153) } [3]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(94) } [4]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(87) } [5]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(77) } [6]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(75) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(65) } [8]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(63) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(60) } [10]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(60) } [11]=> array(2) { ["name"]=> string(17) "Energy Management" ["count"]=> int(57) } [12]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(55) } [13]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(47) } [14]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(46) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(46) } [16]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(45) } [17]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(42) } [18]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(41) } [19]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(36) } [20]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(35) } [21]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(34) } [22]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(28) } [24]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(22) } [28]=> array(2) { ["name"]=> string(6) "Energy" ["count"]=> int(22) } [29]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(21) } } } 81631-us-bristol-myers-squibb-company